Alkem Laboratories has launched generic empagliflozin and its combinations in India under the brand name ‘Empanorm’ at prices that are around 80% lower than the innovator products. Empagliflozin is an SGLT-2 (Sodium-Glucose Co-Transporter-2) inhibitor indicted for use in the treatment of type-2 diabetes mellitus, chronic kidney disease (CKD) and chronic heart failure (HF). The company’s generic empagliflozin and its combinations are bioequivalent to innovator products.
Keeping patient-convenience in mind, the company is offering the medicine in a considerably smaller tablet size than the innovator products. The company’s generic empagliflozin is available under the brand name ‘Empanorm’ and its combinations namely empagliflozin and linagliptin is available under the name ‘Empanorm L’; empagliflozin and sitagliptin is available under the name ‘Empanorm Duo’ and ‘Alsita E’; and empagliflozin and metformin is available under the name ‘Empanorm M’.
Alkem Laboratories is among India’s leading global pharmaceutical companies. The company develops, manufactures and markets high-quality pharmaceutical products across all major therapeutic segments.
Company Name | CMP |
---|---|
Sun Pharma Inds. | 1683.85 |
Dr. Reddys Lab | 1107.85 |
Cipla | 1461.60 |
Lupin | 1969.05 |
Zydus Lifesciences | 882.55 |
View more.. |